CADL
NASDAQ · Biotechnology
Candel Therapeutics Inc
$10.85
-0.49 (-4.32%)
Open$11.28
Previous Close$11.34
Day High$11.38
Day Low$10.78
52W High$14.00
52W Low$4.35
Volume—
Avg Volume1.24M
Market Cap830.61M
P/E Ratio—
EPS$-1.41
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+338.6% upside
Current
$10.85
$10.85
Target
$47.59
$47.59
$33.44
$47.59 avg
$47.92
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 45.25M | 41.90M | 41.45M |
| Net Income | -4,564,062 | -5,052,559 | -4,078,464 |
| Profit Margin | -10.1% | -12.1% | -9.8% |
| EBITDA | -6,328,796 | -6,835,485 | -6,691,447 |
| Free Cash Flow | -4,822,512 | -5,572,664 | -3,889,078 |
| Rev Growth | -8.7% | -6.2% | +3.8% |
| Debt/Equity | 0.84 | 0.77 | 1.12 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |